If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A
PDUFA Target Action Date is March 31, 2023
https://finance.yahoo.com/news/fda-accepts-biomarins-biologics-license-200500695.html
If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A
PDUFA Target Action Date is March 31, 2023
https://finance.yahoo.com/news/fda-accepts-biomarins-biologics-license-200500695.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.